Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor: Contribution to the hypertriglyceridemic action of retinoids

Journal of Clinical Investigation

Volumn 102, Issue 3, 1998, Pages 625-632

  Vu Dac, Ngoc ^a,b   Gervois, Philippe ^a,b   Torra, Inés Pineda ^a,b   Fruchart, Jean Charles ^a,b   Kosykh, Vladimir ^c   Kooistra, Teake ^d   Princen, Hans M G ^d   Dallongeville, Jean ^a,b   Staels, Bart ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIV LILLE   (France)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d TNO   (Netherlands)

Author keywords

Gene regulation; Hyperlipidemia; Nuclear receptors; Retinoids; Triglycerides

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; ALITRETINOIN; APOLIPOPROTEIN C3; BEXAROTENE; CIS ACTING ELEMENT; ISOTRETINOIN; RETINOIC ACID; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL STRAIN HEPG2; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; GENE CONTROL; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN SYNTHESIS; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0032145190     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1581     Document Type: Article

References (62)

1. Marcus, R., and A.M. Coulston. 1996. Fat-soluble vilamins. Vilamins A, K, and E. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics. J.G. Hardman and L.E. Limbird, editors. McGraw-Hill, New York. 1573-1540.
2. Mangelsdorf, D.J., and R.M. Evans. 1445. The RXR heterodimers and orphan receptors. Cell. 83:841-850.
3. Chandraratna, R.A.S., E. Henry, J. Attard, S.J. Gillett, T. Song, M.E. Garst, S. Nagpal, J. Athanikar, T. Arefieg, D.W. Gil, L.A. Wheeler, D. Lew-Kaya, and J. Sefton. 1495. Development of RAR subtype selective retinoids for dermatological diseases. Eur. J. Med. Chem. 30:505s-516s.
4. Boehm, M.F., L. Zhang, B.A. Badea, S.K. White, D.E. Mais, E. Berger, C.M. Suto, M.E. Goldman, and R.A. Heyman. 1994. Synthesis and structure activity of novel retinoid X receptor selective retinoids. J. Med. Chem. 37:2930-2941.
5. Bershad, S., A. Rubinstein, J.R. Paterniti, N.-A. Le, S.C. Poliak, B. Heller, H.N. Ginsberg, R. Fleischmajer, and W.V. Brown. 1985. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N. Engl. J. Med. 313:981-985.
6. Schonfeld, G., P.I. Georges, J. Miller, P. Reilly, and J. Witztum. 1979. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28: 1001-1009.
7. Stocks, J., G. Holdsworth, and D.J. Galton. 1979. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III. Lancet. ii:667-671.
8. Le, N.-A., J.C. Gibson, and H.N. Ginsberg. 1988. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J. Lipid Res. 29:669-677.
9. Malmendier, C.L., J.-F. Lontie, C. Delcroix, D.Y. Dubois, T. Magot, and L. De Roy. 1989. Apolipoprotcins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 77:139-149.
10. Ginsberg, H.N., N.-A. Le, I.J. Goldberg, J.C. Gibson, A. Rubinstein, P. Wang-Iverson, R. Norum, and W.V. Brown. 1986. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78:1287-1295.
11. Dammerman, M., L.A. Sandkuijl, J.L. Halaas, W. Chung, and J.L. Breslow. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90:4562-4566.
12. Rees, A., C.C. Shoulders, J. Stocks, D.J. Galton, and F.E. Baralle. 1983. DNA polymorphism adjacent to human apoprotein A-I gene: relation to hypertriglyceridemia. Lancet. i:444-446.
13. Maeda, N., H. Li, D. Lee, P. Oliver, S.H. Quarfordt, and J. Osada. 1994. Targetted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269:23610-23616.
14. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J.L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249:790-793.
15. de Silva, H.V., S.J. Lauer, J. Wang, W.S. Simonet, K.H. Weisgraber, R.W. Mahley, and J.M. Taylor. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269:2324-2335.
16. Aalto-Setälä, K., E.A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H.N. Ginsberg, and J.L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90:1889-1900.
17. Clavey, V., S. Lestavel-Delattre, C. Copin, J.M. Bard, and J.C. Fruchart. 1995. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler. Thromb. Vasc. Biol. 15:963-971.
18. Aalto-Setälä, K., P.H. Weinstock, C.L. Bisgaier, L. Wu, J.D. Smith, and J.L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apo C-III transgenic mice. J. Lipid Res. 37:1802-1811.
19. Ebara, T., R. Ramakrishnan, G. Steiner, and N.S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99:2672-2681.
20. Wallnöfer, A.E., J.M.T. van Griensven, H.C. Schoemaker, A.F. Cohen, W. Lambert, C. Kluft, P. Meijer, and T. Kooistra. 1993. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. Thromb. Haemost. 70:1005-1008.
21. Leroy, A., N. Vu-Dac, M. Koffigan, V. Clavey, and J.-C. Fruchart. 1988. Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoproteins of human plasma containing apo E. Applications to ELISA quantification of plasma apo E. J. Immunoassay. 9:309-334.
22. Parsy, D., V. Clavey, C. Fievet, I. Kora, P. Duriez, and J.-C. Fruehart. 1985. Quantification of apolipoprotein C-III in serum by noncompetitive immunoenzymometric assay. Clin. Chem. 31:1632-1635.
23. Staels, B., N. Vu-Dac, V.A. Kosykh, R. Saladin, J.C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl coenzyme A oxidase. J. Clin. Invest. 95:705-712.
24. Masiakowski, P., R. Breathnach, J. Bloch, F. Gannon, A. Krust, and P. Chambon. 1982. Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res. 10:7895-7903.
25. Leff, T., K. Reue, A. Melian, H. Culver, and J.L. Breslow. 1989. A regulatory element in the apo CIII promoter that directs hepatic specific transcription binds to proteins in expressing and nonexpressing cell types. J. Biol. Chem. 264:16132-16137.
26. Nakamaye, K.L., and F. Eckstein. 1986. Inhibition of restriction nuclease Ncil cleavage by phosphorothiolate groups and its application to oligonucleotide-directed mutagenesis. Nucleic Acids Res 14:9679-9698.
27. Marsch, J.L., M. Erfle, and E.J. Wykes. 1984. The pIC plasmid and phage vectors with versatile cloning sites for recombinant selection by insertional inactivation. Gene. 32:481-185.
28. Leid, M., P. Kastner, R. Lyons, H. Nakshatri, M. Saunders, T. Zacharewski, J.Y. Chen, A. Staub, J.M. Garnier, S. Mader, and P. Chambon. 1992. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell. 68:377-395.
29. MacGregor, G.K., and C.T. Caskey. 1984. Construction of plasmids that express E. coli β-galactosidase in mammalian cells. Nucleic Acids Res. 17:2365.
30. Kurokawa, R., J. DiRenzo, M. Boehm, J. Sugarman, B. Gloss, M.G. Rosenfeld, R.A. Heyman, and C.K. Glass. 1994. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature. 371: 528-531.
31. Vu-Dac, N., K. Schoonjans, V. Kosykh, J. Dallongeville, R.A. Heyman, B. Staels, and J. Auwerx. 1996. Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell. Biol. 16:3350-3360.
32. Ogami, K., M. Hadzopoulou-Cladaras, C. Cladaras, and V.I. Zannis. 1990. Promoter elements and factors required for hepatic and intestinal transcription of the human apo CIII gene. J. Biol. Chem. 265:9808-9815.
33. Ladias, J.A.A., M. Hadzopoulou-Cladaras, D. Kardassis, P. Cardot, J. Cheng, V. Zannis, and C. Cladaras. 1992. Transcriptional regulation of human apolipoprotein genes apoB, apoCIII, and apoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J. Biol. Chem. 267:15849-15860.
34. Devchand, P.R., H. Keller, J.M. Peters, M. Vazquez, F.J. Gonzalez, and W. Wahli. 1996. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 384:39-43.
35. Melnik, B., U. Bros, and G. Plewig. 1987. Characterization of apoprotein metabolism and atherogenic lipoproteins during oral isotretinoin treatment. Dermatologica. 175(Suppl.):158-168.
36. Vahlquist, C., H. Lithell, G. Michaëlsson, I. Selinus, A. Vahlquist, and B. Vessby. 1987. Plasma fat elimination, tissue lipoprotein lipase activity and plasma fatty acid composition during sequential treatment with etretinate and isotretinoin. Acta Dermatol. Venereol. (Stock.). 67:12-15.
37. Vahlquist, C., I. Selinus, and B. Vessby. 1988. Serum lipid changes during Acitretin (etretin) treatment of psoriasis and palmo-planar pustulosis. Acta Dermatol. Venereol. (Stock.). 68:300-305.
38. Fraser, J.D., D. Keller, V. Martinez, D. Santiso-Mere, R. Straney, and M.R. Briggs. 1997. Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression. J. Biol. Chem. 272:13892-13898.
39. Mietus-Snyder, M., F.M. Sladek, G.S. Ginsburg, C.F. Kuo, J.A.A. Ladias, J.E.J. Darnell, and S.K. Karathanasis. 1992. Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. Mol. Cell. Biol. 12:1708-1718.
40. Staels, B., and J. Auwerx. 1997. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharmaceutical Des. 3:1-14.
41. Peters, J.M., N. Hennuyer, B. Staels, J.-C. Fruchart, C. Fievet, F.J. Gonzalez, and J. Auwerx. 1997. Alterations in lipoprotein metabolism in PPARα-deficient mice. J. Biol. Chem. 272:27307-27312.
42. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J. Biol. Chem. 270:13470-13475.
43. Rottman, J.N., R.L. Widom, B. Nadal-Ginard, V. Mahdavi, and S.K. Karathanasis. 1991. A retinoic acid-responsive element in the apolipoprotein A-I gene distinguishes between two different retinoic acid response pathways. Mol. Cell. Biol. 11:3814-3820.
44. Salerno, A.J., Z. He, A. Goos-Nilsson, H. Ahola, and P. Mak. 1996. Differential transcriptional regulation of the apoAl gene by retinoic acid receptor homo-and heterodimers in yeast. Nucleic Acids Res. 24:566-572.
45. Berthou, L., B. Staels, I. Saldicco, I. Berthelot, J. Casey, J.-C. Fruchart, P. Deǹfle, and D. Branellec. 1994. Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression. Arterioscler. Thromb. 14:1657-1664.
46. Kaptein, A., E.C.M. de Wit, and H.M.G. Princen. 1993. Retinoids stimulate apo A-I synthesis by induction of gene transcription in primary hepatocyte cultures from cynomolgus monkey (Macaea fascicularis). Arterioscler. Thromb. 13:1505-1514.
47. Giller, T., V. Hennes, and H.J. Kempen. 1995. Regulation of human apolipoprotein A-I expression in Caco-2 and HepG2 cells by all-trans and 9-cis retinoic acids. J. Lipid Res. 36:1021-1028.
48. Laker, M.F., C. Green, A.K. Bhuiyan, and S. Shuster. 1987. Isotretinoin and serum lipids: studies on fatty acid, apolipoprotein and intermediary metabolism. Br. J. Dermatol. 117:203-206.
49. O'Leary, T.J., I.E. Simo, N. Kanigsberg, J. Walker, J.C. Goodall, and T.C. Ooi. 1987. Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin. Clin. Invest. Mol. 4:355-360.
50. Vahlquist, C., G. Michaëlsson, A. Vahlquist, and B. Vessby. 1985. A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Br. J. Dermatol. 112:69-76.
51. Zolfaghari, R., and C.A. Ross. 1994. Effect of vitamin A deficiency and retinoic acid repletion on intestinal and hepatic apolipoprotein A-I mRNA levels of adult rats. J. Lipid Res. 35:1985-1992.
52. Gustafson, S., C. Vahlquist, L. Sjöblom, A. Eklund, and A. Vahlquist. 1990. Metabolism of very low density lipoproteins in rats with isotretinoin (13-cis retinoic acid)-induced hyperlipidemia. J. Lipid Res. 31:183-190.
53. Gerber, L., and J. Erdman. 1981. Hyperlipidemia in rats fed retinoic acid. Lipids. 16:496-501.
54. Li, W.W., M.M. Dammerman, J.D. Smith, S. Metzger, J.L. Breslow, and T. Leff. 1995. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 96:2601-2605.
55. Masucci-Magoulas, L., I.J. Goldberg, C.L. Bisgaier, H. Serajuddin, O.L. Francone, J.L. Breslow, and A.R. Tall. 1997. A mouse model with features of familial combined hyperlipidemia. Science. 275:391-394.
56. van der Schroeff, J.G., and H. Jansen. 1985. Post-heparin lipolytic activity and in vitro lipolysis of serum triglycerides during treatment with isotretinoin. In Retinoids: New Trends in Research and Therapy. J. Saurat, editor. Karger, Basel. 466-471.
57. Vahlquist, C. H. Lithell, G. Michaëlsson, A. Vahlquist, and B. Vessby. 1985. Lipoprotein metabolism during sequential treatment with etretinate and isotretinoin in man. In Retinoids: New Trends in Research and Therapy. J. Saurat, editor. Karger, Basel. 472-475.
58. Nagasaki, A., T. Kikuchi, K. Kurata, S. Masushige, T. Hasegawa, and S. Kato. 1994. Vitamin A regulates the expression of apolipoprotein AI and CIII genes in the rat. Biochem. Biophys. Res. Commun. 205:1510-1517.
59. Standeven, A.M., R.L. Beard, A.T. Johnson, M.F. Boehm, M. Escobar, R.A. Heyman, and R.A.S. Chandraratna. 1996. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fundamentals Appl. Toxicol. 33:264-271.
60. Gollnink, H. 1987. New indications and new retinoids. Dermatologica. 175(Suppl.):182-195.
61. Merot, Y., M. Camenzind, J.-M. Geiger, and J.-H. Saurat. 1987. Arotinoid ethyl ester (Ro 13-6298): a long term pilot study in various dermatoses. Acta Dermatol. Venereol. 67:237-242.
62. Kingston, T., S. Gaskell, and R. Marks. 1983. The effects of a novel potent oral retinoid (Ro13-6298) in the treatment of multiple solar keratoses and squamous cell epithelioma. Eur. J. Cancer Clin. Oncol. 19:1201-1205.